GlobeNewswire by notified

Equinor ASA: Buy-back of shares to share programmes for employees

Share

Please see below information about transactions made under the buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR) for shares to be used in the share-based incentive programmes for employees and management.

Date on which the buy-back programme was announced: 8 February 2023.

The duration of the buy-back programme: 15 February 2023 to 15 January 2024.

Size of the buy-back programme: The total purchase amount under the programme is NOK 1,535,150,000 and the maximum shares to be acquired is 20,000,000 shares, of which up to 12,000,000 shares can be acquired in the period from 15 February 2023 to 10 May 2023, and up to 8,000,000 shares can be acquired in the period from 15 June 2023 to 15 January 2024.

On 15 September 2023, Equinor ASA has purchased a total of 352,858 own shares at the Oslo Stock Exchange at an average price of NOK 357.0834 per share.

Aggregated overview of transactions per day:

DateAggregated volume (number of shares)Weighted average share price (NOK)Total transaction value (NOK)
15 September352,858357.0834125,999,734
Previously disclosed buy-backs under the programme (accumulated)2,884,126310.3710895,148,983
Total buy-backs under the programme3,236,984315.46301,021,148,717

Following the completion of the above transactions, Equinor ASA owns a total of 38,385,570 own shares, corresponding to 1.28% of Equinor ASA’s share capital, including shares purchased under the previous buy-back programme for the share-based incentive programmes for employees, and shares purchased under Equinor’s disclosed buy-back programmes which will be used to reduce the issued share capital of the company.

This is information that Equinor ASA is obliged to make public pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Appendix:
A detailed overview of all transactions made under the buy-back programme that have been carried out during the above-mentioned time period is attached to this report and available at www.newsweb.no.

Further information from

Investor relations
Bård Glad Pedersen, senior vice president Investor Relations,
+47 918 01 791

Media
Sissel Rinde, vice president Media Relations,
+ 47 412 60 584


Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration3.10.2023 22:05:00 CEST | Press release

PHAXIAM Therapeutics and Vetophage Announce Strategic ResearchCollaboration Strategic research partnership between PHAXIAM Therapeutics and Vetophage, a biotechnology company specialized in veterinary phage therapy Combining expertise in the research of new phages and phage endolysins that could be applied to human health Exclusive phage and endolysin licensing options in human health for PHAXIAM Therapeutics Lyon (France) and Cambridge (MA, US), October03, 2023 – 10:05pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM) and Vetophage, a company specialized in phage therapy applied to animal health, announce the signature of a long-term strategic research partnership to combine their expertise in the research of new phages and phage-derived proteins (endolysins) in the fight against antimicrobial resistance. Vetophage is a Lyon-based biotechnology company founded in 2017. It develops new tools to detect pathogenic bacteria and alternative solutions to antibiotics based on phages an

Kvika banki hf.: TM Insurance to be sold or listed3.10.2023 21:05:43 CEST | Press release

Following a strategic review at Kvika banki hf. ("Kvika" or "the bank"), the board of directors of Kvika has decided to initiate a process for the sale or listing of its insurance subsidiary TM tryggingar hf. ("TM"). The decision is in line with the bank's vision, where emphasis is placed on simplifying the group's operations and strengthening Kvika's traditional banking activities, in accordance with the bank's goal to increase competition and simplify its customers' finances. Following the divestment of TM, Kvika's main operations will be focused on commercial- and investment banking, along with asset management. It is expected that Kvika's capital base will grow significantly following the divestment of TM, enabling the bank to pursue internal growth opportunities across Kvika's business segments. Increased capital will, among other things, enable the bank to strengthen its market position, in both retail and corporate lending, and increase the risk diversification of its loan book.

Policane® Natural Sweetener Found to Have Low Glycemic Index3.10.2023 20:06:38 CEST | Press release

OCALA, Fla., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Policane®, a natural sweetener made from sugar cane juice in a patented process, has been found to have a low glycemic index (GI) in a study by IFP Suisse SA. According to the study Policane® has a GI of 51.7+/- 3.66. The study also found that Policane® had a 42% lower GI than white sugar. In its conclusion, the study recommends for Policane® a low glycaemic index product classification under International Standard ISO26642. “We are excited to share the results of this study, providing that Policane® is a low-GI sweetener,” said Jorge Enrique Gonzalez, Manager and CEO at PoliCane Co., LLC. “Policane® retains the best parts of the sugar cane stripped away in refined sugar. Policane® is a natural and sustainable sweetener that the world needs.” Policane® is currently produced under license in Costa Rica and can be used in recipes for all sweetened food and beverages, including baked goods, coffee, tea, colas, sauces, ketchup and desserts. Fo

Nokia Corporation: Repurchase of own shares on 03.10.20233.10.2023 20:00:00 CEST | Press release

Nokia Corporation Stock Exchange Release 3 October 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 03.10.2023 Espoo, Finland – On 3 October 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL344,5423.53CEUX39,5413.54AQEU1,3923.53TQEX14,5253.55Total400,0003.53 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023

Adevinta ASA – Procedures established in response to receipt of non-binding indicative proposal3.10.2023 19:30:00 CEST | Press release

Oslo, 3 October 2023 – Adevinta ASA (“Adevinta” or the “Company”) refers to the stock exchange announcement on 21 September 2023 regarding receipt of a non-binding indicative proposal (the “Proposal”) from a consortium led by Permira and Blackstone, with involvement of the Company’s two main shareholders, regarding a potential offer for all shares of the Company. In response to shareholder enquiries, the Company wants to communicate the procedures it is following in response to the Proposal. Immediately upon receipt of the Proposal, the Company’s board of directors established a special committee comprising the five independent directors on the Company’s board. The special committee is representing the Company in all aspects relating to the Proposal. The directors who are representatives of the three main shareholders of the Company are not involved in the Company’s deliberations and decisions. The independent committee is actively engaging in the Proposal in line with applicable regul